Drug Profile
SP 1093V
Alternative Names: SP1-Fe306Latest Information Update: 28 Nov 2007
Price :
$50
*
At a glance
- Originator Supratek Pharma
- Developer Lady Davis Institute for Medical Research; McGill University; Supratek Pharma
- Class Antivirals
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV-1 infections